ASAM Supports Expansion of Access to Buprenorphine Through The Mainstreaming Addiction Treatment Act
ASAM Board Member, Dr. Margaret Jarvis, testified in front of a Congressional Roundtable on the nation’s response to the “third…
Articles
Addiction Medicine Medical Vocabulary
Language Matters We have witnessed remarkable progress in the understanding of the disease of addiction over the past two decades.…
Commentary: Allow Proven Science to Guide Opioid Addiction Treatment
NYSAM board members Dr. Melissa Weimer and Dr. Jeffrey Selzer together with Dr. Daniel Schatz, adjunct assistant professor in the…
“Drunk with Hope”, a play about women in recovery from alcohol to debut in Upstate NY
“Drunk with Hope”, written by Tara Handron, will debut in Syracuse, NY in May. NYSAM board member Dr. Dorothy Lennon…
Buprenorphine Best Practices
The New York State Department of Health, the New York State Office of Alcoholism and Substance Abuse (OASAS), and the New York State Buprenorphine Working Group wrote a Best Practice document focused on misconceptions related to the use of buprenorphine for the treatment of opioid use disorder (OUD). NYSAM Board Member, Dr. Dan Schatz, wrote a summary of the document reviewing five misconceptions of buprenorphine treatment.
To Address the Opioid Overdose Epidemic, Invest in the Next Generation of Addiction Treatment Providers
Melissa Weimer, Jeanette Tetrault, and J. Craig Allen recently published an op-ed in the New Haven Register highlighting the substance…